Updated Guidance and Managed Care Strategies to Optimize Care in EGFR Mutated NSCLC

Program Description

This article provides a review of EGFR mutations and biomarker testing in non-small cell lung cancer (NSCLC), focusing on the clinical implications and therapeutic advancements. EGFR mutations are prevalent and drive tumor growth, necessitating precise biomarker testing for tailored treatment strategies. The article delves into the role of EGFR-targeted therapies, highlighting the efficacy and safety of novel and emerging agents and combination therapies in both frontline and post-progression settings, including the growing interest in investigational antibody-drug conjugates (ADCs) for patients with progressed disease. These therapies have shown significant improvements in efficacy and safety, but inconsistencies in biomarker testing persist. The importance of accurate and timely biomarker testing to guide treatment decisions, barriers to testing, and disparities in access and interpretation will also be discussed. Additionally, the article addresses the pharmacoeconomic considerations and resource utilization associated with EGFR-targeted therapies, examining factors such as adherence, molecular profiling, quality of life, health care resource utilization, and the cost implications of combination therapies. The role of the managed care pharmacist in formulary decision-making, payer strategies, and navigating challenges in biomarker testing will be examined, with a focus on the importance of optimizing resource utilization and ensuring patient access to appropriate therapies.

Target Audience: Managed care pharmacists and oncology pharmacists

Type of Activity: Application
Release date: July 7, 2025
Expiration date: August 7, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the role of biomarker testing in non-small cell lung cancer (NSCLC) and its impact on patient safety, treatment outcomes, and overall cost of care.
• Analyze the results of key clinical trials investigating innovative treatment strategies for patients with EGFR mutation-positive metastatic NSCLC, including novel EGFR tyrosine kinase inhibitors, immunotherapy combinations, and other emerging therapies.
• Examine the roles of oncology and managed care pharmacists in optimizing the use of targeted therapies in advanced EGFR-mutated NSCLC and implementing clinical pathways that enhance care quality, reduce variability, and promote cost-effective treatment strategies.